Farletuzumab ecteribulin is an antibody-drug conjugate (ADC) consisting of the humanized antibody farletuzumab, which targets the folate receptor alpha (FRA), with an antibody-to-drug ratio of 4.0. In vitro, farletuzumab ecteribulin exhibits cytotoxic and antitumor activity against FRA-positive cells.
CAS Number:
[2407465-18-1]
Target:
Antibody-Drug Conjugates (ADCs)
* VAT and and shipping costs not included. Errors and price changes excepted